Trial Profile
Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkins Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors PrECOG
- 23 Mar 2017 Status changed from completed to discontinued due to prolonged enrollment timelines
- 03 Aug 2016 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Planned End Date changed from 1 Jan 2018 to 1 Aug 2016 as reported by ClinicalTrials.gov.